BCIQ Profiles

Company Profile Report
0427 Arch Oncology
BioCentury & Getty Images


Arch pushing anti-CD47 into new settings with $105M series C round

Apr 27, 2021 | 10:30 PM GMT

Arch Oncology, the latest CD47-focused biotech to draw big money with its $105 million series C round, plans to use its new capital to broaden the clinical development program for AO-176 and add new pipeline

Read the full 587 word article

How to gain access

Continue reading with a
two-week free trial.